Serum IgG titer findings for Fusobacterium nucleatum associated with clinical outcome following surgery in patients with esophageal squamous cell carcinoma
PLOS One · 2025
DOI: 10.1371/journal.pone.0336219 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Toru Yoshikawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Fusobacterium nucleatum, Immunoglobulin G, Carcinoma, Squamous Cell. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Fusobacterium nucleatum ( Fn ) is known as an etiological factor related to periodontitis. However, recent reports have shown that it also functions as an oncogenic pathogen and is associated with progression of various cancers as well as poor prognosis of esophageal squamous cell carcinoma (ESCC) patients. The present study was conducted to examine the correlations of serum IgG antibody titer level against Fn (IgG- Fn ) with clinicopathological characteristics, oral conditions, and survival outcomes in 305 patients who underwent an esophagectomy procedure for ESCC. The results revealed that 40.7% of the patients tested positive for IgG- Fn , and those in the positive group had significantly lower rates of overall survival (OS) and cancer-specific survival (CSS) as compared to patients who tested negative (OS; p = 0.01, CSS; p = 0.02). Multivariate analysis showed IgG- Fn positivity as an independent predictor of CSS (hazard ratio, 1.96; 95% CI, 1.32–2.90; p < 0.001). Moreover, among patients who were diagnosed with stage II-IV and underwent neoadjuvant therapy (NAT), those in the IgG- Fn -positive group showed higher pathological progression and greater incidence of inadequate response to NAT as compared to the IgG- Fn -negative group (odds ratio 0.48, 95% CI 0.24–0.92; p = 0.04). The present findings indicate that IgG- Fn can serve as a marker indicating poor tumor response to NAT in advanced ESCC cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
- Department of General Dentistry, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Bacteriology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Hiromi Nishi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Yoshikawa, T., Nishi, H., Emi, M., Hamai, Y., Ibuki, Y., Kurokawa, T., Hirohata, R., Ohsawa, M., Kitasaki, N., Komatsuzawa, H., Kawaguchi, H., & Okada, M. (2025). Serum IgG titer findings for Fusobacterium nucleatum associated with clinical outcome following surgery in patients with esophageal squamous cell carcinoma. PLOS One. https://doi.org/10.1371/journal.pone.0336219
Vancouver
Yoshikawa T, Nishi H, Emi M, Hamai Y, Ibuki Y, Kurokawa T, et al. Serum IgG titer findings for Fusobacterium nucleatum associated with clinical outcome following surgery in patients with esophageal squamous cell carcinoma. PLOS One. 2025. doi:10.1371/journal.pone.0336219
BibTeX
@article{Yoshikawa2025,
author = {Yoshikawa, Toru and Nishi, Hiromi and Emi, Manabu and Hamai, Yoichi and Ibuki, Yuta and Kurokawa, Tomoaki and Hirohata, Ryosuke and Ohsawa, Manato and Kitasaki, Nao and Komatsuzawa, Hitoshi and Kawaguchi, Hiroyuki and Okada, Morihito},
title = {Serum IgG titer findings for Fusobacterium nucleatum associated with clinical outcome following surgery in patients with esophageal squamous cell carcinoma},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0336219}
}
EUVIMED